{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:06:19Z","timestamp":1790946379293,"version":"4.1.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no U.S. Food and Drug Administration-approved therapies for early-stage HS. Topical Janus kinase (JAK) inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signalling in HS lesions and the recent success of systemic JAKi for the treatment of moderate-to-severe HS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the clinical efficacy of ruxolitinib in a pilot cohort and to investigate the underlying biologic mechanisms associated with clinical response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a pilot single-site open-label prospective 24-week clinical trial of topical ruxolitinib (NCT04414514). Men and women with mild HS (Hurley stage I or II), with active inflammatory nodules, were recruited. All participants were observed for 8 weeks to monitor lesion counts (observational phase); active therapy (treatment phase) was then administered for 16 weeks. Topical ruxolitinib 1.5% cream was applied twice daily, covering the entirety of each HS-affected body site. Clinician- and patient-reported outcome measures were recorded throughout the study. Lesional skin punch biopsies were taken at the start and end of treatment for downstream mechanistic RNA sequencing and histological analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten participants were enrolled in the study; four dropped out before the treatment phase of the trial. Six individuals with Hurley stage I (no tunnels) HS completed the study, five of whom successfully achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) through 16 weeks of therapy. In this interim analysis, differential gene expression and gene set enrichment analyses revealed reduced activation of JAK-dependent interferon, interleukin (IL)-6, IL-2 and epidermal growth factor receptor signalling, and antimicrobial and keratinocyte responses. In contrast, signatures of wound healing and lipid metabolism were increased following JAKi treatment, indicating a return to homeostasis. Histological analyses revealed that clinically responsive patients had significantly reduced epidermal and dermal inflammation. Affected inflammatory infiltrate included neutrophils, T cells and plasma cells, with the predominantly affected cell types specific to the patient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Collectively, the broad activity of topical ruxolitinib on inflammatory signalling processes resulted in promising efficacy, even with heterogeneity in baseline inflammation, in this pilot cohort. Importantly, topical treatment not only resolved epidermal inflammation, but also cleared deeper inflammatory infiltrate. The observed efficacy provides rationale to further investigate topical JAKi and other novel topical treatments in HS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae495","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T19:35:33Z","timestamp":1734809733000},"page":"845-856","source":"Crossref","is-referenced-by-count":16,"title":["Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-4938","authenticated-orcid":false,"given":"Stephanie L","family":"Schell","sequence":"first","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4964-3835","authenticated-orcid":false,"given":"Mackenzie L","family":"Sennett","sequence":"additional","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-1872","authenticated-orcid":false,"given":"Robert P","family":"Feehan","sequence":"additional","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tierney E","family":"Wallace","sequence":"additional","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth\u00a0C","family":"Meiszberg","sequence":"additional","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-2789","authenticated-orcid":false,"given":"Amy L","family":"Longenecker","sequence":"additional","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7469-8569","authenticated-orcid":false,"given":"Matthew F","family":"Helm","sequence":"additional","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-3796","authenticated-orcid":false,"given":"Joslyn S","family":"Kirby","sequence":"additional","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-8706","authenticated-orcid":false,"given":"Amanda\u00a0M","family":"Nelson","sequence":"additional","affiliation":[{"name":"The Pennsylvania State University College of Medicine, Department of Dermatology , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"2025042813572048900_ljae495-B1","first-page":"18","article-title":"Hidradenitis suppurativa","volume-title":"Nat Rev Dis Primers","author":"Sabat","year":"2020"},{"key":"2025042813572048900_ljae495-B2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2025042813572048900_ljae495-B5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2025042813572048900_ljae495-B6","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"2025042813572048900_ljae495-B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B8","first-page":"868","article-title":"S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa \u2013 short version","volume":"22","author":"Zouboulis","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025042813572048900_ljae495-B9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B11","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical Janus kinase inhibitors \u2013 a double blind, placebo, and active controlled pilot study","volume":"57","author":"Bokhari","year":"2018","journal-title":"Int J Dermatol"},{"key":"2025042813572048900_ljae495-B12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025042813572048900_ljae495-B13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B16","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jid.2022.01.015","article-title":"Ruxolitinib cream in the treatment of cutaneous lichen planus: a prospective, open-label study","volume":"142","author":"Brumfiel","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025042813572048900_ljae495-B17","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jid.2023.11.027","article-title":"Topical ruxolitinib in the treatment of necrobiosis lipoidica: a prospective, open-label study","volume":"144","author":"Hwang","year":"2024","journal-title":"J\u00a0Invest Dermatol"},{"key":"2025042813572048900_ljae495-B18","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1111\/jdv.18465","article-title":"Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa","volume":"36","author":"Frings","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042813572048900_ljae495-B19","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s00296-023-05418-y","article-title":"Quantitative analysis of JAK\/STAT signaling pathway in patients of inflammatory skin disorders","volume":"44","author":"Demirci Yildirim","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025042813572048900_ljae495-B20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00011-020-01381-7","article-title":"Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis","volume":"69","author":"Rumberger","year":"2020","journal-title":"Inflamm Res"},{"key":"2025042813572048900_ljae495-B21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/bjd\/ljac096","article-title":"Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies","volume":"188","author":"Schell","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/jdv.17779","article-title":"Primary alterations during the development of hidradenitis suppurativa","volume":"36","author":"Dajnoki","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042813572048900_ljae495-B23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"key":"2025042813572048900_ljae495-B24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025042813572048900_ljae495-B25","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"2025042813572048900_ljae495-B26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/jid.2012.476","article-title":"Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step toward personalized therapy","volume":"133","author":"Ingram","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2025042813572048900_ljae495-B27","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","article-title":"Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema","volume":"141","author":"Kirby","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2025042813572048900_ljae495-B28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B30","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B31","doi-asserted-by":"crossref","first-page":"111435","DOI":"10.1016\/j.intimp.2023.111435","article-title":"A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for hidradenitis suppurativa treatment","volume":"127","author":"Heidari","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2025042813572048900_ljae495-B32","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","article-title":"Insights into hidradenitis suppurativa","volume":"149","author":"van Straalen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025042813572048900_ljae495-B33","doi-asserted-by":"crossref","first-page":"e2315096120","DOI":"10.1073\/pnas.2315096120","article-title":"Epigenetic switch reshapes epithelial progenitor cell signatures and drives inflammatory pathogenesis in hidradenitis suppurativa","volume":"120","author":"Jin","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025042813572048900_ljae495-B34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/bjd\/ljad274","article-title":"Spatial transcriptomic profiling reveals the pathophysiology of early-stage hidradenitis suppurativa","volume":"189","author":"Joh","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B35","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa","volume":"136","author":"Hotz","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"2025042813572048900_ljae495-B36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjd.19565","article-title":"Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment","volume":"184","author":"Goldfarb","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B37","first-page":"729","volume-title":"Dermatologic Surgery: Principles and Practice","author":"Hurley","year":"1989"},{"key":"2025042813572048900_ljae495-B38","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042813572048900_ljae495-B39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B40","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/bjd.19798","article-title":"Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument","volume":"184","author":"Zouboulis","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"2025042813572048900_ljae495-B42","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1007\/s00216-018-0964-3","article-title":"MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles","volume":"410","author":"Bonnel","year":"2018","journal-title":"Anal Bioanal Chem"},{"key":"2025042813572048900_ljae495-B43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/exd.13973","article-title":"E-cadherin and p120ctn protein expression are lost in hidradenitis suppurativa lesions","volume":"28","author":"Nelson","year":"2019","journal-title":"Exp Dermatol"},{"issue":"127","key":"2025042813572048900_ljae495-B44","article-title":"New data on the features of skin barrier in hidradenitis suppurativa","volume":"11","author":"Somogyi","year":"2023","journal-title":"Biomedicines"},{"key":"2025042813572048900_ljae495-B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2024.05.027","article-title":"Skin homeostasis is impaired in hidradenitis suppurativa lesions, a comparative study","author":"Soto-Moreno","year":"2024","journal-title":"Actas Dermosifiliogr"},{"key":"2025042813572048900_ljae495-B46","article-title":"Modulation of disease-associated pathways in hidradenitis suppurativa by the Janus kinase 1 inhibitor povorcitinib: transcriptomic and proteomic analyses of two phase 2 studies","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025042813572048900_ljae495-B47","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.jid.2020.04.011","article-title":"Lipidomics profiling of hidradenitis suppurativa skin lesions reveals lipoxygenase pathway dysregulation and accumulation of proinflammatory \u00adleukotriene B4","volume":"140","author":"Penno","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2025042813572048900_ljae495-B48","doi-asserted-by":"crossref","first-page":"a015271","DOI":"10.1101\/cshperspect.a015271","article-title":"Adipocytes in skin health and disease","volume":"4","author":"Rivera-Gonzalez","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025042813572048900_ljae495-B49","doi-asserted-by":"crossref","first-page":"101252","DOI":"10.1016\/j.plipres.2023.101252","article-title":"The skin barrier: an extraordinary interface with an exceptional lipid organization","volume":"92","author":"Bouwstra","year":"2023","journal-title":"Prog Lipid Res"},{"key":"2025042813572048900_ljae495-B50","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B52","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaci.2022.10.034","article-title":"Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa","volume":"151","author":"Sabat","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2025042813572048900_ljae495-B53","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B54","doi-asserted-by":"crossref","first-page":"e139930","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"key":"2025042813572048900_ljae495-B55","first-page":"e169870","article-title":"Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa","volume-title":"JCI Insight","author":"Lowe","year":"2024"},{"key":"2025042813572048900_ljae495-B56","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A proof-of-concept open-\u00adlabel clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","volume":"89","author":"Jepsen","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2025042813572048900_ljae495-B57","first-page":"e139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-\u03b1 therapy","volume-title":"JCI Insight","author":"Lowe","year":"2020"},{"key":"2025042813572048900_ljae495-B58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjd.21060","article-title":"Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum","volume":"187","author":"Navrazhina","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025042813572048900_ljae495-B59","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jid.2023.07.023","article-title":"Rapid attenuation of B-cell and IFN-\u03b3-associated chemokines in clinical responders to Jak inhibition with upadacitinib in hidradenitis suppurativa","volume":"144","author":"Flora","year":"2024","journal-title":"J Invest Dermatol"},{"key":"2025042813572048900_ljae495-B60","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2025042813572048900_ljae495-B61","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.17541","article-title":"\u2018Invasive proliferative gelatinous mass\u2019 of hidradenitis suppurativa contains distinct inflammatory components","volume":"181","author":"Kidacki","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae495\/61253628\/ljae495.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/845\/61253628\/ljae495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/845\/61253628\/ljae495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:57:36Z","timestamp":1745863056000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/5\/845\/7930292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,21]]},"published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae495","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,21]]}}}